Dr Elena Zamagni speaks to ecancer about her presentation at EMN 2024 on 'Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM'.

She explains that the conversation focused on the how to balance clear, non-bias clinical trials with real life patients and trial eligibility.

Dr Zamagni also presented on the combination of daratumumab-VTD in real life and reports that elderly patients with renal failure/high-risk cytogenetics could still benefit from the combination.